Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

Abstract Background To assess the efficacies and potential predictors of a corticosteroid switch in metastatic castration-resistant prostate cancer (mCRPC) patients with biochemical progression on abiraterone acetate plus prednisone (A + P). Methods Patients with mCRPC treated between April 2016 and...

Full description

Bibliographic Details
Main Authors: Zhenyu Yang, Yuchao Ni, Diwei Zhao, Yijun Zhang, Jun Wang, Lijuan Jiang, Dong Chen, Zhiming Wu, Yanjun Wang, Liru He, Yanxia Shi, Fangjian Zhou, Hao Zeng, Yonghong Li
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Cancer
Subjects:
Abiraterone
Castration-resistant prostate cancer
Prednisone
Dexamethasone
Corticosteroid switch
Online Access:https://doi.org/10.1186/s12885-021-08670-2

Internet

https://doi.org/10.1186/s12885-021-08670-2

Similar Items